Clinical Trial Update: A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) [Phase 2]

View source ↗

Summary

Phase 2 study of TAK-007 in adults with relapsed or refractory B-cell non-Hodgkin lymphoma has posted results and remains active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• TAK-007

Snippet

Sponsor: Takeda | Conditions: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-08-12